Run‐Lei Du
Impact in
-
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
- Synthesis and bioactivity of alkaloids
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
Papers in
-
- RNA modifications and cancer 4
- Ubiquitin and proteasome pathways 4
- RNA Research and Splicing 3
- Synthesis and bioactivity of alkaloids 3
- RNA regulation and disease 3
-
- Synthesis and Biological Evaluation 4
- Co-authors
- Shangze Li (15 shared papers)Xiaodong Zhang (14 shared papers)Ze-Yan Zhang (7 shared papers)Rongfu Tu (5 shared papers)Rihui Cao (7 shared papers)Yifan Jia (3 shared papers)Jinxiang Zhang (4 shared papers)Xuemin Song (3 shared papers)
- Journals
- European Journal of Medicinal Chemistry (4 papers)Cell Death and Differentiation (3 papers)Scientific Reports (2 papers)Biochemical and Biophysical Research Communications (2 papers)PLoS ONE (2 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Run‐Lei Du
31 papers receiving 852 citations
Peers
Comparison fields: 5 of 90
- Cancer Research 157
- Molecular Biology 643
- Immunology 124
- Organic Chemistry 133
- Oncology 121
Countries citing papers authored by Run‐Lei Du
This map shows the geographic impact of Run‐Lei Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Run‐Lei Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Run‐Lei Du more than expected).
Fields of papers citing papers by Run‐Lei Du
This network shows the impact of papers produced by Run‐Lei Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Run‐Lei Du. The network helps show where Run‐Lei Du may publish in the future.
Co-authors
The 25 scholars most cited alongside Run‐Lei Du, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 95 | |
| 2 | 2012 | 67 | |
| 3 | 2016 | 60 | |
| 4 | 2013 | 59 | |
| 5 | 2019 | 53 | |
| 6 | 2017 | 47 | |
| 7 | 2018 | 45 | |
| 8 | 2019 | 40 | |
| 9 | 2018 | 35 | |
| 10 | 2017 | 32 | |
| 11 | 2014 | 30 | |
| 12 | 2020 | 29 | |
| 13 | 2014 | 26 | |
| 14 | 2018 | 26 | |
| 15 | 2018 | 23 | |
| 16 | 2013 | 22 | |
| 17 | 2022 | 22 | |
| 18 | 2016 | 22 | |
| 19 | 2018 | 22 | |
| 20 | 2014 | 18 |
About Run‐Lei Du
Run‐Lei Du is a scholar working on Molecular Biology, Organic Chemistry, Cancer Research, Oncology and Immunology, having authored 33 papers that have together received 855 indexed citations. Recurring topics across this work include RNA modifications and cancer (4 papers), MicroRNA in disease regulation (4 papers), Synthesis and Biological Evaluation (4 papers), Ubiquitin and proteasome pathways (4 papers), RNA Research and Splicing (3 papers), Synthesis and bioactivity of alkaloids (3 papers), RNA regulation and disease (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Cancer Research (157 citations), Molecular Biology (643 citations), Immunology (124 citations), Organic Chemistry (133 citations) and Oncology (121 citations). Run‐Lei Du has collaborated with scholars based in China and United States. Frequent co-authors include Shangze Li, Xiaodong Zhang, Ze-Yan Zhang, Rongfu Tu, Rihui Cao, Yifan Jia, Jinxiang Zhang, Xuemin Song, Huihui Zhang and Xiaodong Zhang. Their work appears in journals such as European Journal of Medicinal Chemistry, Cell Death and Differentiation, Scientific Reports, Biochemical and Biophysical Research Communications and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.